The shadow of generic competition has long loomed around copyright’s iconic drug, Sildenafil, raising questions about the future of similar pharmaceutical holdings. While first times saw impressive returns, the intellectual property end has opened the path for discounted substitutes, possibly diminishing revenue and creating a genuine hazard for